163 related articles for article (PubMed ID: 12785806)
1. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
[TBL] [Abstract][Full Text] [Related]
2. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
Ribone SR; Quevedo MA; Madrid M; Briñón MC
J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
[TBL] [Abstract][Full Text] [Related]
3. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
4. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
6. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.
Vingerhoets J; Azijn H; Fransen E; De Baere I; Smeulders L; Jochmans D; Andries K; Pauwels R; de Béthune MP
J Virol; 2005 Oct; 79(20):12773-82. PubMed ID: 16188980
[TBL] [Abstract][Full Text] [Related]
7. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
8. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
Maga G; Amacker M; Ruel N; Hübscher U; Spadari S
J Mol Biol; 1997 Dec; 274(5):738-47. PubMed ID: 9405155
[TBL] [Abstract][Full Text] [Related]
9. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP
Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.
Butini S; Gemma S; Brindisi M; Borrelli G; Fiorini I; Samuele A; Karytinos A; Facchini M; Lossani A; Zanoli S; Campiani G; Novellino E; Focher F; Maga G
Bioorg Med Chem Lett; 2011 Jul; 21(13):3935-8. PubMed ID: 21636271
[TBL] [Abstract][Full Text] [Related]
11. In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor.
Javanbakht H; Ptak RG; Chow E; Yan JM; Russell JD; Mankowski MK; Hogan PA; Hogg JH; Vora H; Hang JQ; Li Y; Su G; Paul A; Cammack N; Klumpp K; Heilek G
Antiviral Res; 2010 May; 86(2):212-9. PubMed ID: 20219553
[TBL] [Abstract][Full Text] [Related]
12. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
13. Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs).
Venkatraj M; Ariën KK; Heeres J; Dirié B; Joossens J; Van Goethem S; Van der Veken P; Michiels J; Vande Velde CM; Vanham G; Lewi PJ; Augustyns K
Bioorg Med Chem; 2011 Oct; 19(20):5924-34. PubMed ID: 21930388
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
15. Substrate-induced stable enzyme-inhibitor complex formation allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resistant HIV-1 reverse transcriptase mutants.
Samuele A; Facchini M; Rotili D; Mai A; Artico M; Armand-Ugón M; Esté JA; Maga G
ChemMedChem; 2008 Sep; 3(9):1412-8. PubMed ID: 18465760
[TBL] [Abstract][Full Text] [Related]
16. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.
Liu J; He X; Zhang JZ
J Mol Model; 2014 Oct; 20(10):2451. PubMed ID: 25234608
[TBL] [Abstract][Full Text] [Related]
17. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
18. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
19. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.
Das K; Clark AD; Lewi PJ; Heeres J; De Jonge MR; Koymans LM; Vinkers HM; Daeyaert F; Ludovici DW; Kukla MJ; De Corte B; Kavash RW; Ho CY; Ye H; Lichtenstein MA; Andries K; Pauwels R; De Béthune MP; Boyer PL; Clark P; Hughes SH; Janssen PA; Arnold E
J Med Chem; 2004 May; 47(10):2550-60. PubMed ID: 15115397
[TBL] [Abstract][Full Text] [Related]
20. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
